Abstract

This study focused on analyzing the differences in efficacy of different doses of mifepristone in the treatment of uterine fibroids. 117 uterine fibroid patients admitted between September 2018 and September 2022 were selected and divided into two groups including 55 patients (control group) receiving 25.0 mg mifepristone oral therapy and 62 patients (research group) receiving 12.5 mg mifepristone oral therapy, both once daily for three menstrual cycles. Clinical evaluation included efficacy, occurrence of adverse drug reactions (dizziness, nausea, vomiting, and elevated alanine aminotransferase level), uterine volume, fibroid volume, and the levels of estradiol, luteinizing hormone, follicle-stimulating hormone, insulin-like growth factor-1, and transforming growth factor-beta 1. The data showed a similar total effective rate in the two groups. However, a markedly lower incidence of adverse drug reactions was determined in the research group vs. the control group. Besides, after treatment the research group had evident reductions in uterine volume, fibroid volume, as well as estradiol, luteinizing hormone, follicle-stimulating hormone, insulin-like growth factor-1, and transforming growth factor-beta 1 levels, which were statistically decreased compared with the control group. Therefore, low-dose mifepristone is equivalent to the conventional dose in treating uterine fibroids, with obvious advantages in medication safety, which will not only significantly reduce the volume of uterus and fibroids, but also inhibit the levels of serum sex hormones and disease progression, thus effectively inhibiting disease deterioration.